Cambrian Bio (Cambrian BioPharma, Inc.) is a New York-based clinical-stage drug development company building therapeutics that target the biological drivers of aging to extend healthspan. It operates as a Distributed Development Company (DisCo), advancing more than a dozen programs through pipeline companies such as Amplifier Therapeutics and Tornado Therapeutics. Its lead asset, ATX-304, is described as the first AMPK Network Activator to enter clinical development and has reported positive Phase 1b results in obesity and prediabetes. Founded in 2019 by CEO James Peyer, the company has raised over $200 million.